
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TWU865. CME credit will be available until December 16, 2026.
Beneath the Surface of Sjögren’s Disease: Understanding Systemic Impact and B-Cell–Mediated Pathways
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education3.5
2727 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TWU865. CME credit will be available until December 16, 2026.
Beneath the Surface of Sjögren’s Disease: Understanding Systemic Impact and B-Cell–Mediated Pathways
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.

696 Listeners

11 Listeners

5 Listeners

11 Listeners

3 Listeners

2 Listeners

5 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

167 Listeners

0 Listeners

9 Listeners

2 Listeners

12 Listeners

2 Listeners

1,394 Listeners

4 Listeners

3 Listeners

5 Listeners

296 Listeners

1,147 Listeners

367 Listeners

34 Listeners